However, in the clinical area, LFA102 had no anti-tumor effect when administered as a single agent in patients with PRLR-positive metastatic BC, questioning the role of PRL in the development of BC and highlighting the need for further studies to fully understand the role of PRLR-driven signaling cascades in tumor growth (10). Here, PRL is linked to breast cancer.